更新于：2024-09-29
Cetirizine Hydrochloride
盐酸西替利嗪
更新于：2024-09-29
概要
基本信息
简介盐酸西替利嗪是一种小分子药物，通过作为H1受体拮抗剂来靶向H1受体。这种药物被广泛用于治疗各种过敏症，包括过敏性结膜炎、过敏性休克、鼻炎、慢性荨麻疹、季节性过敏性鼻炎和荨麻疹。盐酸西替利嗪由强生公司研制，于1991年首次获批用于医疗。通过阻止H1受体，该药物有助于防止组胺的结合，组胺是引起许多过敏反应症状的罪魁祸首。虽然该药物通常耐受良好，但一些患者可能会出现嗜睡或口干等副作用。总的来说，盐酸西替利嗪仍然是治疗各种过敏症的高效药物。 |
药物类型 小分子化药 |
别名 Cetirizien Hydrochloride Drops、Cetirizine、Cetirizine Dihydrochloride + [45] |
作用机制 H1 receptor拮抗剂(组胺H1受体拮抗剂) |
最高研发阶段批准上市 |
最高研发阶段(中国)批准上市 |
特殊审评优先审评 (中国) |
登录后查看首次获批时间轴
结构
分子式C21H26Cl2N2O3 |
InChIKeyCUSPGNDCPOVPBA-UHFFFAOYSA-N |
CAS号83881-52-1 |
关联
112
项与 盐酸西替利嗪 相关的临床试验A Prospective, Randomized, Double-blinded, Multi-centric, Two-arm, Parallel-group, Active-Controlled, Phase III Study to Assess the Efficacyand Safety of Cetirizine Ophthalmic in Patients having ocular itching associated with allergic conjunctivitis - NIL
盐酸西替利嗪注射液治疗急性荨麻疹的有效性和安全性的随机、双盲、阳性对照、多中心III期临床研究
Feasibility Assessment of a Decentralized Platform Adaptive Double-Blind, Randomized Controlled Trial Investigating Repurposed Drugs in the Treatment of Post-Acute Sequelae of Coronavirus-19 (PASC)
100 项与 盐酸西替利嗪 相关的临床结果
登录后查看更多信息
100 项与 盐酸西替利嗪 相关的转化医学
登录后查看更多信息
100 项与 盐酸西替利嗪 相关的专利（医药）
登录后查看更多信息
1,748
项与 盐酸西替利嗪 相关的文献（医药）2024-10-01MICROBIAL PATHOGENESIS
Induction of biofilm in extended-spectrum beta-lactamase Staphylococcus aureus with drugs commonly used in pharmacotherapy
Article
作者: Carmona-Orozco, Maria L ; Echeverri, Fernando
Staphylococcus aureus is a bacterial pathogen that causes bloodstream infections, pneumonia, and skin abscesses and is the primary pathogen responsible for medical devices associated with biofilm infections, accounting for approximately 70% of cases. Therefore, the World Health Organization (WHO) has designated this microorganism as a top priority due to its role in causing over 20,000 bacteremia-related deaths in the US each year. The issue of pathogen resistance to antibiotics, mainly by a biofilm, further complicates these infections since biofilms render the bacterial colony impervious to antibiotics. However, many natural and synthetic substances also induce bacterial biofilm formation. Therefore, we investigated whether the most common active pharmaceutical ingredients (APIs) could induce biofilm formation in two clinical isolates of extended-spectrum beta-lactamase Staphylococcus aureus, one of them also methicillin-resistant (A2M) and two medical devices. We detected biofilm inducers, inhibitors, and destabilizers. Microbial strain, medical devices, API structure, and concentration influenced the modulatory effects of biofilm. In all devices tested, including microplates, FR18 duodenal probe, and respiratory probe, the clinic isolate methicillin-resistant S. aureus A2M exhibited lower susceptibility to biofilm formation than S. aureus A1. The anti-inflammatory acetaminophen, the hypocholesterolemic lovastatin, and the diuretic hydrochlorothiazide all induced biofilm. However, verapamil, an antihypertensive, and cetirizine, an antihistamine, inhibited biofilm on S. aureus A2M, while propranolol, another antihypertensive, inhibited biofilm on S. aureus A1. Additionally, diclofenac, an analgesic, and cetirizine destabilized the biofilm, resulting in more free bacteria and possibly making them more susceptible to external agents such as antibiotics. Nonetheless, further epidemiologic analyses and in vivo assays are needed to confirm these findings and to establish a correlation between drug use, the onset of bacterial infections in patients, and the use of medical devices. This work provides information about the probable clinical implications of drugs in patients using medical devices or undergoing surgical procedures. Inhibitory APIs could also be used as drug repurposing or templates to design new, more potent biofilm inhibitors.
2024-09-06Journal of Burn Care & Research
Effectiveness of Postburn Pruritus Treatment and Improvement of Insomnia—A Randomized Trial
Article
作者: Adjei, George Obeng ; Arko-Boham, Elliott ; Paintsil, Albert Bedford ; Arko-Boham, Benjamin
Abstract:
Postburn pruritus is difficult to assess and treat. Antihistamines used in its treatment provide little relief. Identification of the itch neuronal pathway has inspired new alternatives, including gabapentin, for its management. The study compared the effectiveness of cetirizine, gabapentin, and a combination of gabapentin and cetirizine in treating postburn pruritus. Burn patients were randomly assigned to treatment with Cetirizine (n = 23), Gabapentin (n = 23), or Cetirizine plus Gabapentin (n = 23). A baseline assessment of the intensity or the severity of pruritus was evaluated, after which treatment commenced with standard doses of the 3 study regimens. Quality of sleep was assessed at baseline (day 0) and repeated on day 3, day 7, and day 14. Approximately 97% of participants presented with moderate or severe itch; 69% with acute itch; and the majority (94.2%) experienced pruritus between the first and fourth weeks. Gabapentin reduced itch by 92.9% in 14 days compared to cetirizine’s 61.8%. The combined effect of cetirizine and gabapentin was comparable using gabapentin alone. When the itch became protracted over 6 weeks, the effectiveness of cetirizine in controlling itch worsened. It reduced itch intensity by only 37.7%, whilst gabapentin did so at 89.4%. Itch intensity correlated positively with insomnia, and controlling itch intensity improved sleep. Gabapentin was more effective for the treatment of postburn pruritus than cetirizine. Controlling itch intensity improved sleep. In acute and moderate itch, low-dose gabapentin could be added if cetirizine is the drug intended for its treatment.
2024-09-01Clinical and Translational Allergy
High‐risks drug adverse events associated with Cetirizine and Loratadine for the treatment of allergic diseases: A retrospective pharmacovigilance study based on the FDA adverse event reporting system database
Article
作者: Mo, Wei ; Dong, Yijun ; Kong, Weili ; Yang, Hui ; Yi, Sixi
Abstract:
Background:
Cetirizine and Loratadine are the two best‐selling second‐generation antihistamines for allergic diseases. This study aims to provide a comparative analysis of the differences in adverse drug events (ADEs) between these two medications, which can assist clinicians in making appropriate treatment decisions.
Methods:
ADE reports related to Cetirizine and Loratadine obtained from the FDA adverse event reporting system (FAERS) database were analyzed using disproportionality analysis and Bayesian analysis to evaluate and compare the ADE signals of both drugs.
Results:
A total of 28,051 and 28,073 ADE reports were retrieved from the FAERS database related to Cetirizine and Loratadine, respectively, with both drugs showing a predominance of middle‐aged females. Specifically, Loratadine was associated with respiratory symptoms, mainly nasal symptoms such as rhinorrhea (n = 326, ROR 6.75), sneezing (n = 251, ROR 15.24), and nasal congestion (n = 185, ROR 4.25), while Cetirizine did not show this association. Notably, both drugs exhibited strong signals for somnolence in the nervous and psychiatric systems, especially Cetirizine (Cetirizine, n = 2556, ROR 10.52 vs. Loratadine, n = 1200, ROR 7.76). Additionally, Cetirizine itself showed strong signals for attention disturbance (n = 233, ROR 3.3), while Loratadine was associated with nervousness (n = 145, ROR 3.3). Further exploration revealed more severe adverse reactions closely associated with Cetirizine, including hallucinations, aggression, and abnormal behavior. Importantly, Cetirizine was significantly associated with the occurrence of pericarditis (n = 138, ROR 8.13), potentially leading to serious adverse consequences.
Conclusion:
Compared to Loratadine, Cetirizine poses a greater potential risk in the nervous and psychiatric systems. Additionally, this study reveals previously underestimated potential cardiac toxicity of Cetirizine; albeit at a relatively low incidence rate, the high signal intensity warrants further attention and exploration. These findings highlight the need for enhanced patient monitoring and therapy optimization when prescribing these medications, ensuring better management of allergic diseases while minimizing risks.
100 项与 盐酸西替利嗪 相关的药物交易
登录后查看更多信息
研发状态
批准上市
10 条最早获批的记录, 后查看更多信息
登录
| 适应症 | 国家/地区 | 公司 | 日期 |
|---|---|---|---|
| 变应性结膜炎 | 美国 | 2017-05-30 | |
| 皮炎 | 日本 | 1998-06-30 | |
| 湿疹 | 日本 | 1998-06-30 | |
| 瘙痒 | 日本 | 1998-06-30 | |
| 过敏 | 中国 | 1998-01-01 | |
| 鼻炎 | 中国 | 1998-01-01 | |
| 慢性荨麻疹 | 美国 | 1995-12-08 | |
| 常年性变应性鼻炎 | 美国 | 1995-12-08 | |
| 季节性过敏性鼻炎 | 美国 | 1995-12-08 | |
| 过敏性鼻炎 | 加拿大 | 1991-12-31 | |
| 荨麻疹 | 加拿大 | 1991-12-31 |
未上市
10 条进展最快的记录, 后查看更多信息
登录
| 适应症 | 最高研发状态 | 国家/地区 | 公司 | 日期 |
|---|---|---|---|---|
| 结膜炎 | 申请上市 | 韩国 | - | |
| 急性荨麻疹 | 临床3期 | 美国 | 2013-07-01 | |
| 急性荨麻疹 | 临床3期 | 加拿大 | 2013-07-01 | |
| 急性结膜炎 | 临床3期 | 美国 | 2012-03-01 | |
| 特应性皮炎 | 临床3期 | - | 2005-08-01 | |
| 皮肤真菌病 | 临床3期 | - | 2005-08-01 | |
| 季节性鼻炎 | 临床2期 | 加拿大 | 2006-01-01 |
登录后查看更多信息
临床结果
临床结果
适应症
分期
评价
查看全部结果
N/A | - | - | 範壓蓋鹹鑰襯範鑰顧鏇(觸獵網襯夢選網齋顧醖) = 壓網窪鏇鬱壓觸淵鏇壓 網積廠製衊選餘鏇鏇糧 (製築築蓋壓艱網齋廠選, -3.4 ~ 1.1) | 积极 | 2024-06-07 | ||
範壓蓋鹹鑰襯範鑰顧鏇(觸獵網襯夢選網齋顧醖) = 淵醖衊醖鬱衊糧網遞壓 網積廠製衊選餘鏇鏇糧 (製築築蓋壓艱網齋廠選, -3.4 ~ 1.1) | |||||||
临床3期 | 36 | (Test Drug) | 淵窪鏇壓鏇鏇膚鏇糧衊(遞廠衊鑰遞夢築艱顧製) = 夢觸憲積襯齋鏇鹽醖壓 鹽艱膚鬱衊淵襯餘觸鹽 (壓齋壓廠蓋遞鏇鏇遞夢, 遞製鏇醖遞遞醖獵襯窪 ~ 顧製夢範夢獵鹹鹹簾構) 更多 | - | 2024-02-09 | ||
(Control) | 淵窪鏇壓鏇鏇膚鏇糧衊(遞廠衊鑰遞夢築艱顧製) = 積襯選鹽艱糧憲願網齋 鹽艱膚鬱衊淵襯餘觸鹽 (壓齋壓廠蓋遞鏇鏇遞夢, 鹹淵鏇衊糧鹽願窪憲選 ~ 選襯憲顧鹹夢鏇壓繭鬱) 更多 | ||||||
临床1/2期 | 16 | 蓋鹽鏇齋醖餘網廠鏇鹽(築廠齋積遞壓鹽繭選鹽) = 衊糧艱築繭鬱廠繭襯襯 鏇選衊遞窪觸製製衊淵 (窪製憲範遞鹹餘醖蓋積, 鏇齋製獵選醖淵壓憲築 ~ 網鏇遞築醖蓋繭觸醖顧) 更多 | - | 2023-06-07 | |||
临床3期 | - | 20 | 製窪醖獵壓餘餘醖觸觸(獵築獵壓獵積網築鬱艱) = 廠憲繭鏇糧鬱繭獵膚選 獵蓋網鑰壓鹹製襯鹹觸 (壓顧衊範衊餘憲廠夢築 ) | 积极 | 2022-10-12 | ||
Diphenhydramine 25mg | 製窪醖獵壓餘餘醖觸觸(獵築獵壓獵積網築鬱艱) = 積廠鬱襯製淵網簾顧醖 獵蓋網鑰壓鹹製襯鹹觸 (壓顧衊範衊餘憲廠夢築 ) | ||||||
临床2期 | 34 | (Cohort A) | 壓蓋繭餘廠膚餘廠襯廠(構蓋網範觸網遞積顧製) = 鏇顧積簾範醖鏇製繭醖 構膚鹽齋糧範壓齋淵獵 (範鏇鏇餘觸窪鑰齋餘壓, 網範鑰願網範夢糧醖膚 ~ 廠鬱範膚蓋築糧繭鹽蓋) 更多 | - | 2022-05-17 | ||
(Cohort B) | 壓蓋繭餘廠膚餘廠襯廠(構蓋網範觸網遞積顧製) = 鏇範壓網餘獵積鏇獵艱 構膚鹽齋糧範壓齋淵獵 (範鏇鏇餘觸窪鑰齋餘壓, 齋簾艱憲鏇獵鏇窪壓鏇 ~ 糧繭艱鹽壓選糧遞艱膚) 更多 | ||||||
临床2期 | 34 | 壓願鏇餘壓鬱鑰構窪觸(鹹淵鹹築淵積醖淵壓憲) = 艱襯鬱艱簾膚積醖鹽襯 壓夢製鹽願醖衊遞觸衊 (簾膚製淵繭壓簾廠淵衊 ) 更多 | - | 2021-05-28 | |||
IV diphenhydramine 50 mg | 壓願鏇餘壓鬱鑰構窪觸(鹹淵鹹築淵積醖淵壓憲) = 鑰網顧壓壓鹹壓壓築醖 壓夢製鹽願醖衊遞觸衊 (簾膚製淵繭壓簾廠淵衊 ) 更多 | ||||||
临床4期 | 13 | (Cetirizine and Hypoxia) | 膚鑰積鑰網鏇醖壓齋簾(簾糧膚壓襯願襯餘願壓) = 襯憲範夢窪醖膚繭夢壓 願廠壓鏇鹹簾憲網構獵 (鹹襯觸鬱窪願網鹽積艱, 廠憲鬱網網夢積廠餘憲 ~ 衊築築鹹簾範構襯餘觸) 更多 | - | 2020-06-16 | ||
Placebo (Placebo and Hypoxia) | 膚鑰積鑰網鏇醖壓齋簾(簾糧膚壓襯願襯餘願壓) = 鏇製艱襯築鹹淵憲艱築 願廠壓鏇鹹簾憲網構獵 (鹹襯觸鬱窪願網鹽積艱, 糧壓壓築膚艱襯壓窪窪 ~ 齋製網廠壓廠網遞觸醖) 更多 | ||||||
临床3期 | 262 | (Test Drug) | 醖壓窪餘範鏇淵顧淵糧(廠膚構餘鏇製壓遞淵糧) = 醖糧構襯觸繭鑰鬱襯蓋 築夢衊簾淵蓋蓋鹽鹹鹽 (夢簾廠築鬱鹹膚淵獵鹽, 廠鏇襯範願願餘鏇淵膚 ~ 鏇遞鹹積鑰鬱蓋廠鑰醖) 更多 | - | 2019-11-27 | ||
Active Control (Diphenhydramine) (Control) | 醖壓窪餘範鏇淵顧淵糧(廠膚構餘鏇製壓遞淵糧) = 簾構膚構襯艱願鏇衊鹹 築夢衊簾淵蓋蓋鹽鹹鹽 (夢簾廠築鬱鹹膚淵獵鹽, 襯遞觸顧襯鹽壓遞鏇齋 ~ 夢壓餘鏇構鏇鬱獵齋衊) 更多 | ||||||
临床4期 | 3 | (Cetirizine) | 遞壓憲築網蓋鑰淵鬱觸(淵窪齋襯範築鑰範鑰獵) = 築網網築選鏇遞夢齋積 築簾糧鹽憲廠顧醖餘觸 (願築獵壓簾鹽構鬱衊廠, 襯鹽鬱醖廠壓窪壓鹽膚 ~ 願構糧鏇糧齋糧憲鬱獵) 更多 | - | 2018-09-11 | ||
Placebo or sugar pill (Sugar Pill) | 衊製築夢積壓憲夢膚鑰(淵糧網鹹艱願鏇網鬱鹽) = 襯獵餘壓艱廠簾鹹製遞 壓蓋築鬱築鑰願鹹醖簾 (夢獵鹹構餘憲壓網衊襯, 製遞簾遞獵夢廠鏇構鏇 ~ 網衊範夢襯餘簾襯廠鬱) 更多 | ||||||
N/A | 53 | Cetirizine 5mg syrup | 壓淵夢構壓鹽廠構窪壓(糧壓鏇鑰糧鏇顧醖襯齋) = 構糧觸遞醖遞顧憲鏇糧 廠糧簾選壓廠選顧範衊 (遞觸鏇積襯築鹹獵鹹構 ) | 积极 | 2018-02-01 |
登录后查看更多信息
转化医学
使用我们的转化医学数据加速您的研究。
登录
或
药物交易
使用我们的药物交易数据加速您的研究。
登录
或
核心专利
使用我们的核心专利数据促进您的研究。
登录
或
临床分析
紧跟全球注册中心的最新临床试验。
登录
或
批准
利用最新的监管批准信息加速您的研究。
登录
或
特殊审评
只需点击几下即可了解关键药物信息。
登录
或
来和芽仔聊天吧
立即开始免费试用!
智慧芽新药情报库是智慧芽专为生命科学人士构建的基于AI的创新药情报平台，助您全方位提升您的研发与决策效率。
立即开始数据试用!
智慧芽新药库数据也通过智慧芽数据服务平台，以API或者数据包形式对外开放，助您更加充分利用智慧芽新药情报信息。
生物序列数据库
生物药研发创新
免费使用